Predicting acute myocardial infarction with a single blood draw by Boeddinghaus, Jasper et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Predicting acute myocardial infarction with a single blood draw
Boeddinghaus, Jasper ; Nestelberger, Thomas ; Badertscher, Patrick ; Twerenbold, Raphael ; Fitze,
Brigitte ; Wussler, Desiree ; Strebel, Ivo ; Rubini Giménez, Maria ; Wildi, Karin ; Puelacher, Christian ;
du Fay de Lavallaz, Jeanne ; Oehen, Loris ; Walter, Joan ; Miró, Òscar ; Martin-Sanchez, F Javier ;
Morawiec, Beata ; Potlukova, Eliska ; Keller, Dagmar I ; Reichlin, Tobias ; Mueller, Christian ; APACE
Investigators, ?
Abstract: BACKGROUND: We desired to determine cardiac troponin (cTn) concentrations necessary to
achieve a positive predictive value (PPV) of ￿75% for acute myocardial infarction (AMI) to justify imme-
diate admission of patients to a monitored unit and, in general, early coronary angiography. METHODS:
In a prospective multicenter diagnostic study enrolling patients presenting to the emergency department
with symptoms suggestive of AMI, final diagnoses were adjudicated by 2 independent cardiologists based
on clinical information including cardiac imaging. cTn concentrations were measured using 5 different
sensitive and high-sensitivity cTn (hs-cTn) assays in a blinded fashion at presentation and serially there-
after. The diagnostic end point was PPV for rule-in of AMI of initial cTn concentrations alone and in
combination with early changes. RESULTS: Among 3828 patients, 616 (16%) had an AMI. At presenta-
tion, 7% to 14% of patients had cTnT/I concentrations associated with a PPV of ￿75%. Adding absolute
or relative changes did not significantly further increase the PPV. PPVs increased from 46.5% (95% CI,
43.6-49.4) for hs-cTnT at presentation >14 ng/L to 78.9% (95% CI, 74.7-82.5) for >52 ng/L (P < 0.001),
whereas PPVs in higher hs-cTnT strata remained largely unchanged [e.g., 82.4% (95% CI, 77.5-86.7) for
>80 ng/L vs 83.9% (95% CI, 76.0-90.1) for >200 ng/L (P = 0.72)]. The addition of early changes in
hs-cTnT further increased the PPV up to 60 ng/L, but not for higher concentrations. CONCLUSIONS:
Serial sampling does not seem necessary for predicting AMI and concurrent decision-making in about
10% of patients, as it only marginally increases the PPV for AMI and not in a statistically or clinically
significant way. CLINICALTRIALSGOV IDENTIFIER: NCT00470587.
DOI: https://doi.org/10.1373/clinchem.2018.294124
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-181681
Journal Article
Published Version
Originally published at:
Boeddinghaus, Jasper; Nestelberger, Thomas; Badertscher, Patrick; Twerenbold, Raphael; Fitze, Brigitte;
Wussler, Desiree; Strebel, Ivo; Rubini Giménez, Maria; Wildi, Karin; Puelacher, Christian; du Fay de
Lavallaz, Jeanne; Oehen, Loris; Walter, Joan; Miró, Òscar; Martin-Sanchez, F Javier; Morawiec, Beata;
Potlukova, Eliska; Keller, Dagmar I; Reichlin, Tobias; Mueller, Christian; APACE Investigators, ? (2019).
Predicting acute myocardial infarction with a single blood draw. Clinical Chemistry, 65(3):437-450.
DOI: https://doi.org/10.1373/clinchem.2018.294124
Predicting Acute Myocardial Infarction with a Single
Blood Draw
Jasper Boeddinghaus,1,2,3† Thomas Nestelberger,1,3† Patrick Badertscher,1,3 Raphael Twerenbold,1,3,4
Brigitte Fitze,1 Desiree Wussler,1,2,3 Ivo Strebel,1,3 Maria Rubini Gime´nez,1,3 Karin Wildi,1,3
Christian Puelacher,1,3 Jeanne du Fay de Lavallaz,1,3 Loris Oehen,1 Joan Walter,1,3 O`scar Miro´,3,5
F. Javier Martin-Sanchez,3,6 Beata Morawiec,3,7 Eliska Potlukova,1,2 Dagmar I. Keller,8 Tobias Reichlin,1,3 and
Christian Mueller1,3* for the APACE Investigators
BACKGROUND: We desired to determine cardiac troponin
(cTn) concentrations necessary to achieve a positive pre-
dictive value (PPV) of 75% for acute myocardial in-
farction (AMI) to justify immediate admission of pa-
tients to a monitored unit and, in general, early coronary
angiography.
METHODS: In a prospective multicenter diagnostic study
enrolling patients presenting to the emergency depart-
ment with symptoms suggestive of AMI, final diagnoses
were adjudicated by 2 independent cardiologists based on
clinical information including cardiac imaging. cTn con-
centrations were measured using 5 different sensitive and
high-sensitivity cTn (hs-cTn) assays in a blinded fashion
at presentation and serially thereafter. The diagnostic end
point was PPV for rule-in of AMI of initial cTn concen-
trations alone and in combination with early changes.
RESULTS: Among 3828 patients, 616 (16%) had an AMI.
At presentation, 7% to 14% of patients had cTnT/I con-
centrations associated with a PPV of75%. Adding ab-
solute or relative changes did not significantly further
increase the PPV. PPVs increased from 46.5% (95% CI,
43.6–49.4) for hs-cTnT at presentation 14 ng/L to
78.9% (95% CI, 74.7–82.5) for52 ng/L (P 0.001),
whereas PPVs in higher hs-cTnT strata remained largely
unchanged [e.g., 82.4% (95% CI, 77.5–86.7) for 80
ng/L vs 83.9% (95% CI, 76.0–90.1) for 200 ng/L
(P  0.72)]. The addition of early changes in hs-cTnT
further increased the PPV up to 60 ng/L, but not for
higher concentrations.
CONCLUSIONS: Serial sampling does not seem necessary
for predicting AMI and concurrent decision-making in
about 10% of patients, as it only marginally increases the
PPV for AMI and not in a statistically or clinically signif-
icant way.
CLINICALTRIALS.GOV IDENTIFIER: NCT00470587.
© 2018 American Association for Clinical Chemistry
Patients with symptoms suggestive of an acute myocar-
dial infarction (AMI)9 such as chest discomfort or angina
pectoris account for up to 10% of all emergency depart-
ment (ED) presentations (1 ). Immediate identification
of AMI as a life-threatening disorder is critical for the
early initiation of an appropriate evidence-based therapy.
For the safe and rapid rule-out or rule-in of AMI, elec-
trocardiography (ECG) and cardiac troponin (cTn) com-
plement clinical assessment and form the 3 essential di-
agnostic cornerstones (2, 3 ).
The introduction of sensitive cardiac troponin (s-
cTn) and high-sensitivity cardiac troponin (hs-cTn) as-
says enabled the precise measurement of cTn concentra-
tions around the 99th percentile and even in the reference
interval (4, 5 ), and thereby substantially improved the
diagnostic accuracy for AMI at presentation (6, 7 ). How-
ever, the clinical introduction of hs-cTn assays also led to
substantial uncertainty among clinicians on how to best
use them (1–3 ). According to current recommendations,
hs-cTn concentrations should be interpreted quantita-
tively with higher concentrations indicating a higher like-
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lihood for the presence of AMI (1–3 ). Although guide-
lines recommend the use of 2 measurements of cTn in the
early diagnosis of AMI to quantify early hs-cTn changes,
a recent pilot study questioned the general need for serial
sampling for rule-in of AMI (8 ).
Because the concept of rapid rule-in of AMI based
on a single measurement of cTn has enormous medical
and economic appeal (1–3 ), we aimed to determine the
cTn concentrations necessary to achieve a positive pre-
dictive value (PPV) of 75% for AMI using 5 different
s-cTn and hs-cTn assays in a large multicenter diagnostic
study. Such threshold concentrations could be applied to
justify immediate admission to a monitored unit and, in
general, early coronary angiography.
Materials and Methods
STUDY DESIGN AND POPULATION
Advantageous Predictors of Acute Coronary Syndrome
Evaluation (APACE) is an ongoing prospective interna-
tional multicenter study with 12 centers in 5 European
countries aiming to advance the early diagnosis of AMI
(ClinicalTrials.gov registry, number NCT00470587)
(6, 9–16).
Adult patients presenting to the ED with symptoms
suggestive of AMI (such as acute chest discomfort and
angina pectoris) with an onset or peak within the past
12 h were recruited. Although enrollment was irrespec-
tive of renal function, patients with terminal kidney fail-
ure on chronic dialysis were excluded. The study was
carried out according to the principles of the Declara-
tion of Helsinki and approved by the local ethics com-
mittees. Written informed consent was obtained from
all patients.
For this analysis, patients were excluded if they had
ST-segment elevation myocardial infarction or an un-
known diagnosis after adjudication and at least 1 in-
creased hs-cTnT concentration possibly indicating AMI
(for whom 3 independent cardiologists were not able to
make a final diagnosis).
The authors designed the study, gathered and ana-
lyzed the data according to the STARD guidelines for stud-
ies of diagnostic accuracy (see Table 1 in the Data Supple-
ment that accompanies the online version of this article at
http://www.clinchem.org/content/vol65/issue3), vouched
for the data and analysis, wrote the paper, and decided to
publish.
ROUTINE CLINICAL ASSESSMENT
Patients underwent clinical assessment that included
medical history, physical examination, standard blood
test including serial measurements of local hs-cTn, 12-
lead ECG, chest radiography, continuous ECG rhythm
monitoring, and pulse oximetry. Treatment of patients
was left to the discretion of the attending physician.
ADJUDICATED FINAL DIAGNOSIS
Adjudication of the final diagnosis was performed by 2
independent cardiologists at the core laboratory (Univer-
sity Hospital Basel) applying the universal definition of
AMI using 2 sets of data: first, all available medical re-
cords obtained during clinical care including history,
physical examination, results of laboratory testing includ-
ing serial clinical hs-cTn determinations, radiologic test-
ing, ECG, echocardiography, cardiac exercise test, lesion
severity, and morphology in coronary angiography per-
taining to the patient from the time of ED presentation
to 90-day follow-up evaluation; second, study-specific
assessments including detailed chest pain characteristics
using 34 predefined criteria, serial hs-cTnT blood con-
centrations obtained from study samples, and clinical
follow-up by telephone and/or mail. In situations of dis-
agreement about the diagnosis, cases were reviewed and
adjudicated in conjunction with a third cardiologist. To
address the uncommon, but previously described, phe-
nomenon of discrepant results for hs-cTnT and hs-cTnI,
we performed a second adjudication using serial hs-cTnI
(rather than hs-cTnT) blood concentrations from study
samples.
It needs to be highlighted that patients’ care at all
participating study sites was left to the discretion of the
attending physicians and that serial sampling of study-
specific hs-cTn concentrations was independent from lo-
cal triage protocols and time points of blood draws for
local cTn measurements (e.g., at study sites using a 0/6-h
protocol, samples were taken locally at 0 h and 6 h and at
1 h, 2 h, and 3 h for study purposes only).
AMI was defined and hs-cTn interpreted as recom-
mended in the current guidelines (17–19). In brief, myo-
cardial infarction was diagnosed when there was evidence
of myocardial necrosis in association with a clinical set-
ting consistent with myocardial ischemia. Myocardial ne-
crosis was diagnosed by at least 1 cTn value above the
99th percentile, together with a significant rise and/or
fall. The criteria used to define a rise and/or fall in con-
ventional cTn and hs-cTnT are described in detail in the
Methods section found in the online Data Supplement.
All other patients were classified in the categories of un-
stable angina, noncardiac chest pain, cardiac but non-
coronary disease (e.g., tachyarrhythmias, perimyocardi-
tis), and symptoms of unknown origin with normal
concentrations of hs-cTnT.
INVESTIGATIONAL hs-cTn MEASUREMENTS
Blood samples for determination of hs-cTnT and the
other (h)s-cTn assays were collected into tubes contain-
ing potassium EDTA or serum, respectively. Additional
samples were collected at 1 h, 2 h, and 3 h after presen-
tation. Serial sampling was discontinued when a patient
was released or transferred to the catheter laboratory for
acute treatment. After centrifugation, samples were fro-
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zen at 80 °C until assayed in a blinded fashion at a
dedicated core laboratory.
The hs-cTnT assay (Elecsys 2010, Roche Diagnos-
tics) has a 99th percentile concentration of 14 ng/L with
a corresponding CV of 10% at 13 ng/L (4 ). The limit of
blank and limit of detection have been determined to be
3 ng/L and 5 ng/L, respectively (4 ). None of the hs-cTnT
measurements in this analysis were affected by the 2010
to 2012 calibration shift (20, 21 ). Estimated glomerular
filtration rate was calculated using the abbreviated Mod-
ification of Diet in Renal Disease formula (22 ). Investi-
gational (h)s-cTn measurements using the other 4 assays
can be found in the Methods section of the online Data
Supplement.
FOLLOW-UP AND CLINICAL END POINTS
Patients were contacted 3, 12, and 24 months after dis-
charge by telephone calls or in written form. Addition-
ally, information regarding death during the follow-up
period was obtained from the patient’s hospital notes, the
family physician’s records, and the national registry on
mortality. The primary outcome measure was prediction
of AMI as quantified by the resulting PPVs.
STATISTICAL ANALYSIS
Continuous variables are represented as median values
with interquartile range, categorical variables by num-
bers, and percentages. Differences in PPVs were assessed
using the Pearson 2 test.
As an example, for hs-cTnT we stratified patients
according to concentrations at presentation of14 ng/L,
14 ng/L,30 ng/L,52 ng/L,60 ng/L,80 ng/L,
100 ng/L, 200 ng/L, and 400 ng/L. Sensitivity
analyses were performed to assess the diagnostic perfor-
mance of (h)s-cTn by resulting sensitivities, negative pre-
dictive values, specificities, PPV, and diagnostic odds ra-
tios for the respective (h)s-cTn cutoffs alone and in
combination with early absolute and relative changes
within 1 h, 2 h, and 3 h. Relative changes were defined
consistently throughout all assays as a change in cTn
concentrations of 10% within 1 h and 20% within
2 h or 3 h. Absolute changes were assay-specific as de-
scribed previously, e.g., 5 ng/L within 1 h and 10
ng/L within 2 h or 3 h for hs-cTnT by the Elecsys
(16, 23, 24 ) (see the online Data Supplement). Patients
with highly increased cTn concentrations at presentation
but final diagnoses other than AMI were further investi-
gated. Subgroup analyses were performed in patients
with type 1 myocardial infarction only (instead of type 1
and type 2 myocardial infarction) and in patients with
ST-depression and/or T-wave inversions in the ECG.
We did not adjust for multiple testing. To minimize
the risk of false-positive findings (P  0.05 for differ-
ences in PPV despite no real difference for 1 assay at 1
time point), we have prioritized the analysis for hs-cTnT,
as this is the largest data set available in APACE (primary
analysis) and because hs-cTnT is the only hs-cTn assay
currently approved for clinical use in the US by the Food
and Drug Administration (1 ). The analyses with the 4
other (h)s-cTnI assays were performed to investigate
whether the findings for hs-cTnT are generalizable to the
other (h)s-cTn assays.
All hypothesis testing was 2-tailed, and P values
0.05 were considered statistically significant. Statistical
analyses were performed using SPSS for Windows (ver-
sion 24.0, SPSS), R (version 3.3.1, “epiR 0.9.79”), and
MedCalc (version 9.6.4.0, MedCalc Software).
Results
CHARACTERISTICS OF PATIENTS
From April 2006 to August 2015, a total of 3828 patients
were eligible for the analyses for hs-cTnT and 3548 for
hs-cTnI (see Fig. 1 in the online Data Supplement). Pa-
tients with highly increased hs-cTnT or hs-cTnI concen-
trations at presentation more often had ECG changes
such as ST-segment depressions or T-wave inversions
and higher rates of coronary angiography and percutane-
ous coronary interventions (Table 1; see also Table 2 in
the online Data Supplement). Similar findings emerged
using the 4 (h)s-cTnI assays (see Tables 3–5 in the online
Data Supplement).
ADJUDICATED FINAL DIAGNOSIS
The adjudicated final diagnosis was AMI in 616 of 3828
patients (16%), unstable angina in 364 of 3828 (9%),
cardiac symptoms of origin other than coronary artery
disease such as tachyarrhythmias, takotsubo cardiomyop-
athy, heart failure, or myocarditis in 565 of 3828 (15%),
noncardiac symptoms in 2125 of 3828 (56%), and un-
known in 158 of 3828 patients (4%). The proportion of
patients with AMI increased with higher hs-cTnT con-
centrations at presentation (Fig. 1A). Similar findings
emerged using the 4 (h)s-cTnI assays (Fig. 1B; see also
Figs. 2–4 in the online Data Supplement). Non-hs-cTn
assays were used in 1860 of 3828 (49%) patients and
hs-cTn assays were used in 1968 of 3828 (51%) patients
for clinical care at different study sites.
AVAILABLE SAMPLES AT EACH TIME POINT
For hs-cTnT (Elecsys), 3828 patients had available 0-h
samples, 3123 of 3828 patients (82%) had available
1-h samples, 2586 of 3828 patients (68%) had available
2-h samples, and 1508 of 3828 patients (39%) had avail-
able 3-h samples.
For hs-cTnI (Architect), 3548 patients had available
0-h samples, 2828 of 3548 patients (80%) had available
1-h samples, 2272 of 3548 patients (64%) had
available 2-h samples, and 1153 of 3548 patients (32%)
had available 3-h samples. Numbers of available samples
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for the other 3 (h)s-cTnI assays are given in the online
Data Supplement. Missing cTn concentrations taken as
part of the study at 1 h, 2 h, and 3 h can be explained as
a result of logistics issues in the EDs and/or diagnostic
procedures performed around the 1-h to 3-h windows.
DIAGNOSTIC PERFORMANCE OF DIFFERENT hs-cTnT
CONCENTRATIONS AT PRESENTATION
The resulting PPVs for prediction of AMI increased from
46.5% (95% CI, 43.6–49.4) for hs-cTnT 14 ng/L to
78.9% (95% CI, 74.7–82.5) for52 ng/L (P 0.001),
whereas PPVs in higher hs-cTnT strata remained largely
unchanged (Table 2). Similar findings emerged using the
4 (h)s-cTnI assays (see Tables 6–9 in the online Data
Supplement). Assay-specific cutoffs to achieve pre-
defined PPVs of 70% and 75% or greater were highly
variable among 4 different cTnI assays, and in general at
least twice as high as the necessary cTnT concentration
(Table 3).
DIAGNOSTIC PERFORMANCE OF DIFFERENT (h)s-cTn
CONCENTRATIONS AT PRESENTATION ACCORDING TO THE
SECONDARY ADJUDICATION INCLUDING hs-cTnI (ARCHITECT)
Using the secondary adjudication, PPVs for the (h)s-
cTnI assays were higher compared with the primary ad-
judication. However, findings regarding the additional
value of early changes remained unchanged (see Tables
10–13 in the online Data Supplement).
DIAGNOSTIC PERFORMANCE OF EARLY ABSOLUTE AND
RELATIVE hs-cTnT CHANGES IN ADDITION TO hs-cTnT
CONCENTRATIONS AT PRESENTATION
Addition of early changes in hs-cTnT further increased
the PPV for AMI up to an initial hs-cTnT concentra-
Fig. 1. Final diagnoses according to hs-cTn concentrations at presentation.
(A), hs-cTnT; (B), hs-cTnI (Architect). UA, unstable angina.
Predicting AMI with a Single Blood Draw
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tion of 60 ng/L, but not for higher concentrations
(Fig. 2A). The addition of absolute and relative 1-h
changes to hs-cTnT concentrations at presentation
14 ng/L substantially increased and nearly doubled
PPVs from 46.5% (95% CI, 43.6 – 49.4) to 82.3%
(95% CI, 78.0 – 86.1) and 71.8% (95% CI, 66.8 –
76.4; both P  0.001), respectively. Adding absolute
and relative 2-h and 3-h changes also increased PPVs
significantly (all P 0.001). In patients with hs-cTnT
concentrations at presentation 30 ng/L [PPV,
69.4% (95% CI, 65.6 –73.0)] or 52 ng/L [PPV,
78.9% (95% CI, 74.7– 82.5)], the addition of absolute
1-h changes resulted in significantly higher PPVs of
84.7% (95% CI, 80.1– 88.6; P  0.001) and 85.5%
(95% CI, 80.6 – 89.4; P  0.03), respectively. Similar
results were found for the addition of relative 1-h
changes to hs-cTnT concentrations at presentation
30 ng/L and 52 ng/L with resulting PPVs of
85.8% (95% CI, 80.6 –90.2; P  0.001) and 87.8%
(95% CI, 81.8 –92.1; P  0.01), respectively.
In patients with hs-cTnT concentrations at pre-
sentation 60 ng/L, neither the addition of early ab-
solute nor relative changes significantly improved the
resulting PPVs compared with PPVs provided by hs-
cTnT concentrations at presentation alone. Similar
findings emerged using the other 4 (h)s-cTnI assays
and when using the secondary adjudication (Fig. 2B;
see also Figs. 2– 4 and Tables 10 –13 in the online Data
Supplement).
DIAGNOSTIC PERFORMANCE OF DIFFERENT hs-cTnT
CONCENTRATIONS AT PRESENTATION IN PATIENTS WITH
TYPE 1 MYOCARDIAL INFARCTION
The resulting PPVs for prediction of type 1 myocardial
infarction were slightly lower compared with PPVs for
the composite of type 1 and type 2 myocardial infarction.
PPVs increased from 40.6% (95% CI, 37.8–43.4) for
hs-cTnT 14 ng/L to 71.2% (95% CI, 66.7–75.4) for
52 ng/L (P 0.001), whereas PPVs in higher hs-cTnT
strata remained largely unchanged [e.g., 75.9% (95% CI,
70.6–80.4) for hs-cTnT 80 ng/L vs 78.8% (95% CI,
70.6–85.2) for hs-cTnT 200 ng/L (P  0.52)].
DIAGNOSTIC PERFORMANCE OF DIFFERENT hs-cTnT
CONCENTRATIONS AT PRESENTATION IN COMBINATION
WITH SIGNS OF MYOCARDIAL ISCHEMIA ON THE ECG
The presence of an ischemic ECG (ST-depression and/or
T-wave inversion) in addition to hs-cTnT concentra-
tions further increased the PPVs for prediction of AMI
[e.g., 46.5% (95% CI, 43.6–49.4) for hs-cTnT 14
ng/L without ECG changes vs 58.3% (95% CI, 53.6–
63.0) for hs-cTnT14 ng/L with ECG changes; 78.9%
(95% CI, 74.7–82.5) for hs-cTnT 52 ng/L without
ECG changes vs 84.2% (95% CI, 78.4–88.7) for hs-
cTnT 52 ng/L with ECG changes]. However, the ad-
dition of an ischemic ECG significantly reduced the
number of patients eligible for rule-in of AMI (e.g., 1193
patients with hs-cTnT14 ng/L without ECG changes
vs 420 patients with hs-cTnT 14 ng/L and ECG
changes).
PATIENTS WITH HIGHLY INCREASED hs-cTnT
CONCENTRATIONS AT PRESENTATION BUT FINAL DIAGNOSES
OTHER THAN AMI
Among patients with highly increased hs-cTnT concen-
trations at presentation but final diagnosis other than
AMI, the vast majority had cardiac, but not coronary,
disease such as hypertensive crisis, myocarditis, heart fail-
ure, tachyarrhythmias, and takotsubo cardiomyopathy
(see Table 14 in the online Data Supplement).
Discussion
This large multicenter study was performed to determine
the cTn concentrations necessary to achieve a PPV of
75% for AMI to justify immediate admission to a mon-
itored unit and, in general, early coronary angiography.
We report 6 major findings.
First, increasing strata of (h)s-cTn concentrations
were associated with increasing probability of AMI. Sec-
ond, depending on the hs-cTnT/I assay used, 7% to 14%
of patients had cTnT/I concentrations associated with a
PPV of 75%. Third, the necessary cTn concentration
to achieve a PPV of75% was highly variable among 5
hs-cTnT/I assays, and in general at least twice as high for
Table 3. Assay-speciﬁc cutoff concentrations to achieve
predeﬁned PPVs.
Number of
patients (%)
hs-cTnT Elecsys
Cutoff >30 ng/L for PPV of about ≥70% 641 (17%)
Cutoff > 52 ng/L for PPV of about ≥75% 417 (11%)
hs-cTnI Architect
Cutoff >100 ng/L for PPV of about ≥70% 411 (12%)
Cutoff >300 ng/L for PPV of about ≥75% 246 (7%)
hs-cTnI Vista
Cutoff >100 ng/L for PPV of about ≥70% 245 (13%)
Cutoff >200 ng/L for PPV of about ≥75% 177 (9%)
hs-cTnI Beckman Coulter
Cutoff >40 ng/L for PPV of about ≥70% 178 (16%)
Cutoff >80 ng/L for PPV of about ≥75% 138 (13%)
s-cTnI Ultra
Cutoff >60 ng/L for PPV of about ≥70% 415 (15%)
Cutoff > 80 ng/L for PPV of about ≥75% 364 (14%)
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the hs-cTnI assays compared with the corresponding hs-
cTnT concentration. Fourth, the addition of absolute
and relative 1-h, 2-h, and 3-h changes significantly in-
creased PPVs only in patients with mild hs-cTnT/I in-
creases at presentation, e.g., up to 60 ng/L for hs-cTnT,
but not in patients with even higher concentrations.
Fifth, our findings were confirmed using a secondary
adjudication including serial measurements of hs-cTnI
(Architect) rather than hs-cTnT (Elecsys). This at least in
part overcomes the inherent bias when using 1 specific
hs-cTn for final adjudication. Sixth, the findings were
comparable in patients with type 1 myocardial infarc-
tion, and PPVs could be improved further by addition of
an ischemic ECG.
Our findings corroborate and extend previous work
on the optimization of the early and accurate rule-in of
AMI (14–16, 23, 25, 26 ). The introduction of hs-cTn
assays increased diagnostic accuracy for AMI at presenta-
tion by their higher sensitivity, which allowed the detec-
tion of low-risk patients for early rule-out of AMI
(6, 7, 10, 13, 16, 23, 27, 28 ). However, because of the
higher sensitivity and the frequent detection of increased
cTn concentrations in patients with conditions other
than AMI, clinical specificity for AMI at the 99th per-
centile decreased substantially. Thus, for physicians the
accurate rule-in of AMI has become more challenging
owing to a wider range of other diagnoses with increased
cTn concentrations to be considered. The extent of train-
ing and continuous medical education needed for emer-
gencymedicinespecialists,cardiologists,andinternalmedi-
cine specialists to appropriately interpret hs-cTn
concentrations has been largely underestimated (1–3 ).
To facilitate the rule-in of AMI, the additional use of
absolute or relative changes in addition to cTn concen-
trations at presentation has become the recommended
strategy (9, 29–34). The findings of this study provide
further support for this strategy, with the clear exception
of patients presenting with cTn concentrations 3 to 5
times the 99th percentiles, as the resulting PPVs could
not further be improved by the addition of early changes.
The ability to achieve a high enough PPV with a
single blood draw is expected to substantially reduce the
time needed for the management decisions associated
with the triage toward rule-in of AMI including admis-
sion to a monitored unit and, in general, early coronary
angiography (1–3 ). The vast majority of patients triaged
toward rule-in with a diagnosis other than AMI such as
myocarditis, takotsubo cardiomyopathy, and acute heart
failure will still require treatment in a monitored unit.
Similarly, most patients triaged toward rule-in with a
diagnosis other than AMI may still require coronary an-
giography for reliable diagnosis. The acceleration and
simplification of patient pathways by decision-making
based on a highly increased cTn concentration obtained
from a single blood draw may be associated with im-
proved medical and economic outcomes (1–3 ).
It is important to highlight that serial sampling for
cTn until the peak cTn concentration has been reached
should still remain the standard of care, as it is an ac-
cepted method of estimating infarct size (1–3 ). However,
waiting for the results of serial sampling should not cause
a delay in the management decision necessary early in the
ED.
Our study has several important strengths. First, our
study is a multicenter study with nearly 4000 patients.
Therefore, this analysis has appropriate power to detect
clinically meaningful differences in PPVs between differ-
ent strategies. Second, we used a strong methodology for
the adjudication of the final diagnosis including all avail-
able medical records obtained during clinical care, car-
diac imaging, serial clinical (h)s-cTn concentrations, as
well as study-specific assessments including serial hs-
cTnT (primary adjudication) or hs-cTnI (secondary ad-
judication) blood concentrations obtained from study
samples and follow-up evaluations. Third, we examined
several (h)s-cTn assays to maximize the generalizability of
findings.
It is important to highlight that all strategies for
rule-in of AMI should always be used in conjunction
with all other information available to the clinicians in-
cluding vital signs, the 12-lead ECG, and chest pain char-
acteristics (2 ). Therefore, PPVs for rule-in may increase
when combining cTn concentrations with ECG changes
or specific chest pain characteristics.
Some limitations merit consideration when inter-
preting these findings. First, our study was conducted in
ED patients with symptoms suggestive of AMI. Further
studies are required to quantify the utility of single cTn
concentrations to predict AMI in patients with either a
higher pretest probability (e.g., in a coronary care unit
setting) or a lower pretest probability (e.g., in a general
practitioner setting) for AMI. Second, no specific sample
size calculation was performed. Although this secondary
analysis from an ongoing multicenter study is 1 of the
largest ever performed, it still may have been underpow-
ered for some comparisons. Third, we did not adjust for
multiple testing. To minimize the risk of false-positive
findings, we have prioritized the analysis for hs-cTnT, as
this was the assay with the most data available in our
study. Fourth, not all patients with acute chest pain had
laboratory measurements at 1 h, 2 h, and 3 h. The most
common reasons for missing blood samples were logistics
issues in the ED, early transfer to the catheter laboratory
or coronary care unit, and diagnostic procedures that
precluded blood draws. However, it is unlikely that the
absence of these patients meaningfully influenced our
results. Fifth, although we used a strong methodology to
adjudicate the presence or absence of AMI including cen-
tral adjudication by experienced cardiologists and serial
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Fig. 2. PPVs for AMI of hs-cTn concentrations at presentation alone and in combination with absolute and relative changes.
(A), hs-cTnT concentrations at presentation alone and in combination with relative and absolute changes within 1 h, 2 h, and 3 h. (B), hs-cTnI
(Architect) concentrations at presentation alone and in combination with relative and absolute changes within 1 h, 2 h, and 3 h.
Predicting AMI with a Single Blood Draw
Clinical Chemistry 65:3 (2019) 447
D
ow
nloaded from
 https://academ
ic.oup.com
/clinchem
/article-abstract/65/3/437/5607978 by U
niversitaetsbibliothek Bern user on 05 February 2020
Fig. 2—Continued
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measurements of hs-cTn, we still may have misclassified a
small number of patients. Sixth, our findings are specific
to the investigated (h)s-cTn assays. Three of the 5 assays
are not clinically available (e.g., the Beckman Coulter
assay is an experimental prototype). Before possible clin-
ical use, thresholds should be externally validated. Once
other assays become available, additional studies will be
needed to examine whether our findings can be general-
ized to those assays. Seventh, we cannot generalize our
findings to patients with terminal kidney failure requir-
ing dialysis because they were excluded from this study.
Eighth, there is no universal consensus on what PPV is
sufficient in an individual patient to proceed with imme-
diate admission to a monitored unit and/or early coro-
nary angiography. Although the specific threshold pre-
defined for this analysis (75%) is in agreement with
current guideline recommendations, the finding of a lack
of further improvement in PPV with serial sampling is
not affected by the PPV threshold used.
In conclusion, serial sampling does not seem neces-
sary for rule-in of AMI and concurrent decision-making
in about 10% of patients with suspected AMI at presen-
tation, as it only marginally increases the PPV for AMI
and not in a statistically or clinically significant way. The
respective hs-cTnT/I concentration achieving a high-
enough PPV for immediate triage toward rule-in is assay-
dependent and highly variable. Physicians need to famil-
iarize themselves in detail with the hs-cTnT/I assay(s)
used at their institution to best be able to apply these
assays.
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